Formosa Pharmaceuticals, Inc.

Formosa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Taipei City, Taiwan, focused on developing drug candidates in ophthalmology, oncology, and anti-infectives. Its pipeline includes TSY-110, an antibody-drug conjugate; TSY-0210, an antibiotic for drug-resistant infections; APP13002 for infectious eye diseases such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction; and MPT0E028, a pan-histone deacetylase inhibitor for solid tumors including hepatomas and colorectal cancer. The company has strategic partnerships with Eyenovia, Inc. for novel ophthalmic therapeutics and with the Singapore Eye Research Institute for ophthalmic formulations for corneal diseases. Formosa Pharmaceuticals was founded in 2010.